Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
CNS Pharmaceuticals, Inc. (“CNS,” the “Company,” “we,” “us,” or “our”) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need. Significant progress has been made in the biological and molecular understanding of these diseases, enabling a shift to high-value disease-modifying therapies and precision medicine approaches. Together with advancements in diagnostic capabilities to aid in patient selection, there is the potential to improve the probability of success and reduce development timelines. We believe this combination of scale, urgency, and scientific development creates compelling opportunities for differentiated therapeutic approaches and novel mechanisms of action. Our executive team was purposefully built to focus on high-value therapeutic opportunities in these therapeutic areas and the Company is working to build a differentiated portfolio of assets with best-in-class potential to address significant unmet medical needs. CNS Pharmaceuticals is committed to advancing novel treatments that have the potential to improve patient outcomes. Recent Developments On January 1, 2026, the Company appointed Rami Levin, MBA, as President & Chief Executive Officer. Following Mr.
Read the full filing description · filed 31 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
Source: SEC filings. Information and analytics, not investment advice.